179 related articles for article (PubMed ID: 19157266)
1. An update on the platelet dysfunction in chronic myeloproliferative syndromes.
Vlădăreanu AM; Ciufu C; Bumbea H; Onisâi M; Aramă S
Rom J Intern Med; 2008; 46(1):9-15. PubMed ID: 19157266
[TBL] [Abstract][Full Text] [Related]
2. [Pathogenesis of thrombotic and hemorrhagic complications in myeloproliferative and myelodysplastic syndromes].
Vlădăreanu AM; Popov V; Bumbea H; Ciufu C; Vasilache V; Petre A; Onisâi M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):14-9. PubMed ID: 21688554
[TBL] [Abstract][Full Text] [Related]
3. Platelet dysfunction in acute leukemias and myelodysplastic syndromes.
Vlădăreanu AM; Vasilache V; Bumbea H; Onisâi M
Rom J Intern Med; 2011; 49(1):93-6. PubMed ID: 22026258
[TBL] [Abstract][Full Text] [Related]
4. [Platelet defects in chronic myeloproliferative disorders].
Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
[TBL] [Abstract][Full Text] [Related]
5. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
6. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
7. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
8. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
[No Abstract] [Full Text] [Related]
9. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
Vannucchi AM; Guglielmelli P
Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
[No Abstract] [Full Text] [Related]
11. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
12. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
Cortelazzo S; Barbui T; Bassan R; Dini E
Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
[TBL] [Abstract][Full Text] [Related]
13. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes].
Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J
Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850
[No Abstract] [Full Text] [Related]
14. Platelet abnormalities in myeloproliferative disorders.
Holme S; Murphy S
Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
[TBL] [Abstract][Full Text] [Related]
15. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Bojko P; Abenhardt W; Schnittger S; Haferlach T
Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
[TBL] [Abstract][Full Text] [Related]
17. Platelet abnormality with no response to PGD2 in a patient with metastatic pancreas carcinoma and myeloproliferative disorder.
Kariya T; Suzuki H; Saito H; Higashihara M; Yamanaka M
Nihon Ketsueki Gakkai Zasshi; 1987 Feb; 50(1):168-74. PubMed ID: 3473883
[No Abstract] [Full Text] [Related]
18. Platelets and thrombosis in myeloproliferative diseases.
Harrison CN
Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
[TBL] [Abstract][Full Text] [Related]
19. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
20. Circulating activated platelets in myeloproliferative disorders.
Wehmeier A; Tschöpe D; Esser J; Menzel C; Nieuwenhuis HK; Schneider W
Thromb Res; 1991 Feb; 61(3):271-8. PubMed ID: 1709309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
